AI Summary

South African researchers have launched a clinical trial evaluating “off‑the‑shelf” immune cells for patients whose lymphoma has returned or is resistant to standard therapy. The study employs genetically engineered natural‑killer (NK) cells derived from a common laboratory cell line rather than individualized patient‑specific products. investigators are monitoring safety and seeking early signs that the shared NK cells can benefit individuals with specific B‑cell lymphoma subtypes.

AI summaries can be wrong sometimes—always verify important details using the source article.